Dataset opportunity
Med X Press — Inspection Reports Dataset Opportunity
Moderate inspection reports dataset held by Med X Press, usable for Document Intelligence and Defect Detection.
Score
69.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Intelligent Document Processing market was valued at USD 10.41 billion in 2025, projected to grow at a CAGR of 26.8% (2026-2034).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Inspection Reports Dataset
Modality
Document
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Document-AI / IDP vendors
Med X Press holds a specialized Document modality dataset centered on pharmaceutical logistics, comprising `inspection_records`, regulatory filings, and related `transaction_data`. This Inspection Reports Dataset is exceptionally well-suited for training Document Intelligence models to automate the extraction, classification, and compliance verification from complex, regulated documents, with associated `iot_data` providing further contextual integrity.
The global Intelligent Document Processing market was valued at USD 10.41 billion in 2025 and is projected to grow with a CAGR of 26.8%, demonstrating immense demand for this data type. While access involves navigating shared data ownership with clients and a highly regulated environment under pharmaceutical law, the dataset's rarity and applicability in such a high-growth market present a compelling value proposition for buyers aiming to lead in healthcare automation. ⚠ Diligence (valuable data, access to negotiate): Data ownership is shared with pharmaceutical clients for specific product flows.; Highly regulated environment (narcotics, pharmaceutical law § 47.3) requires strict compliance.; Recent acquisition by SK Pharma Group may centralize decision-making. · corporate: subsidiary of SK Pharma Group.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Med X Press owns a proprietary dataset of inspection reports generated from its highly regulated pharmaceutical logistics operations. This is a high-value asset for Document AI and IDP vendors seeking to train models on complex, real-world pharmaceutical documentation. In a market projected to grow at a 26.8% CAGR, this rare dataset offers a significant competitive advantage by enabling the automation of document intelligence for the healthcare supply chain.
See dimension details ↓- Dataset Specificity100
dominant 'inspection_records', sector healthcare, 4 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity94
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value94
fit for Document Intelligence
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is exceptionally high, driven by the rapid 26.8% CAGR of the Intelligent Document Processing market, for which this type of regulated document data is a critical training asset.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, subsidiary of SK Pharma Group
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 evidence types, 4 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
subsidiary of SK Pharma Group
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Med X Press is an ideal target, being an owner-managed SME in pharmaceutical logistics whose core business of transport, storage, and handling of sensitive goods like narcotics generates valuable, dormant operational data. Issues: The company was recently acquired by the SK Pharma Group, which could change its SME status or data strategy in the future, though for now, it is stated that op
- Deep Qualification80
⚠ needs review — Med X Press is a specialized pharma logistics service provider, making it a data holder. The hypothesized 'Inspection Reports Dataset' is highly coherent with its core business, but the data is generated on behalf of clients, making ownership mixed and resale rights highly restricted by regulation and contracts. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Regulatory records
This text confirms the holder generates documentation related to pharmaceutical serialization and anti-counterfeit measures, which is critical for training AI models on supply chain compliance and security.
IoT / sensor data
This indicates the presence of time-series data from temperature-controlled warehouses, providing essential context for cold-chain logistics and quality assurance documents.
Inspection reports
This is direct evidence of visual inspection reports for sensitive products like syringes, vials, and even narcotics, representing a core, high-value document type for any advanced document processing model.
Transaction data
This tabular data proves the existence of transactional records for legally compliant pharmaceutical shipments, essential for training models to process invoices and manifests governed by specific drug laws.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Med X Press Inspection Reports — a Moderate inspection reports dataset (Document modality) in the healthcare domain. Primary AI use-case: Document Intelligence. Market signal: Global Intelligent Document Processing market was valued at USD 10.41 billion in 2025, projected to grow at a CAGR of 26.8% (2026-2034) (source: Fortune Business Insights).. Investment score 69.8/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Forestcarbon — Knowledge Base Dataset Opportunity
View opportunity →healthcareEndiatx — Medical Imaging Dataset Opportunity
View opportunity →healthcareAktiia — Sensor Telemetry Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Your Specialized Images Are Rare3 min read
- Acquire Rare, Compliant Data3 min read
- Is Your Data Worth Money?3 min read